Figure 2.
Kaplan-Meier estimate of total overall survival (A), regorafenib overall survival (B), and regorafenib progression-free survival (C) for the sorafenib and lenvatinib groups of HCC patients. HCC, hepatocellular carcinoma.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.